Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death

Hepatology

Volumn 40, Issue 4, 2004, Pages 802-810

  Heuman, Douglas M ^a,b   Abou Assi, Souheil G ^a,b   Habib, Adil ^a,b   Williams, Leslie M ^a   Stravitz, R Todd ^a   Sanyal, Arun J ^a   Fisher, Robert A ^a   Mihas, Anastasios A ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM ION;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MELD SCORE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SODIUM BLOOD LEVEL; SOLDIER; UNITED STATES; VALIDATION PROCESS;

EID: 4644301244     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.1840400409     Document Type: Article

References (34)

1. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858.
2. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Botg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000;31:864-871.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
5. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003;52:134-139.
6. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.
7. Freeman RB Jr. Around the world with the model for end- stage liver disease. Liver Transpl 2003;9:1118-1119.
8. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease. HEPATOLOGY 2001;33:473-475.
9. Merion RM, Wolfe RA, Dykstta DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003;9:12-18.
10. Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl 2003;9:19-21.
11. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathological characteristics. Am J Med 1965;39:184-198.
12. Arroyo V, Rodes J, Gutierrez-Lizatraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256.
13. Arroyo V, Bosch J, Gaya-Beltran J, Kravetz D, Estrada L, Rivera F, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981;94:198-201.
14. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487.
15. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987;7:122-128.
16. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266.
17. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
18. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23:164-176.
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
20. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
21. Wiesner RH, Edwards E, Freeman R, Harper A. Does the Model for End stage Liver Disease (MELD) predict post liver transplant graft survival. HEPATOLOGY 2003;38:371A.
22. Heuman DM, Mihas A. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 2003;125:992-993.
23. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathological characteristics. Am J Med 1965;39:184-198.
24. Arroyo V, Bosch J, Gaya-Beltran J, Kravetz D, Estrada L, Rivera F, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981;94:198-201.
25. Arroyo V, Bernardi M, Epstein M, Henriksen JH, Schrier RW, Rodes J. Pathophysiology of ascites and functional renal failure in cirrhosis. J Hepatol 1988;6:239-257.
26. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69-S89.
27. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003;124:634-641.
28. Guardiola J, Xiol X, Escriba JM, Castellvi JM, Castellote J, Baliellas C, et al. Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt. Am J Gastroenterol 1995;90:2097-2102.
29. Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991;325:829-835.
30. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323-328.
31. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
32. Shetty K, Sonnad S, Olthoff KM, Shaked A, Reddy RK. Impact of the MELD score on resource utilization following liver transplantation. HEPATOLOGY 2003;38:367A.
33. Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003;9:117-123.
34. Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, et al. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003;9:473-476.